Thu, March 13, 2025
Wed, March 12, 2025

Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal

  Copy link into your clipboard //business-finance.news-articles.net/content/202 .. -and-endo-to-merge-in-nearly-7-billion-deal.html
  Print publication without navigation Published in Business and Finance on by Reuters
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
Mallinckrodt and Endo , drugmakers with a shared history of facing U.S. opioid litigation, have agreed to merge in a deal valued at nearly $7 billion.
Mallinckrodt and Endo International, two major pharmaceutical companies, have agreed to merge in a deal valued at nearly $7 billion. This merger aims to combine their strengths in specialty pharmaceuticals, particularly in areas like pain management, addiction treatment, and other critical therapies. The merger comes at a time when both companies have faced significant legal and financial challenges, including lawsuits related to the opioid crisis. The combined entity is expected to enhance their market position, streamline operations, and potentially mitigate some of the financial pressures through cost savings and a broader product portfolio. The deal is subject to regulatory approval and other customary closing conditions.

Read the Full Reuters Article at:
[ https://www.msn.com/en-ca/money/other/drugmakers-mallinckrodt-and-endo-to-merge-in-nearly-7-billion-deal/ar-AA1APVsF ]


Similar Business and Finance Publications